ValuEngine downgraded shares of Kura Oncology (NASDAQ:KURA) from a hold rating to a sell rating in a research report released on Friday.
Several other research firms have also weighed in on KURA. Zacks Investment Research lowered shares of Kura Oncology from a buy rating to a hold rating in a report on Wednesday, October 18th. Citigroup set a $13.00 target price on shares of Kura Oncology and gave the stock a buy rating in a report on Tuesday, August 8th. Cowen initiated coverage on shares of Kura Oncology in a report on Thursday, September 7th. They issued an outperform rating on the stock. Leerink Swann reiterated an outperform rating and issued a $18.00 target price (up from $16.00) on shares of Kura Oncology in a report on Thursday, August 10th. Finally, Cann reiterated a buy rating on shares of Kura Oncology in a report on Wednesday, November 8th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company’s stock. Kura Oncology presently has a consensus rating of Buy and an average target price of $17.60.
Shares of Kura Oncology (NASDAQ KURA) traded down $0.70 during midday trading on Friday, reaching $15.35. 192,200 shares of the company traded hands, compared to its average volume of 289,491. The company has a current ratio of 13.48, a quick ratio of 13.48 and a debt-to-equity ratio of 0.07. Kura Oncology has a fifty-two week low of $4.95 and a fifty-two week high of $17.50.
Kura Oncology (NASDAQ:KURA) last posted its earnings results on Tuesday, November 7th. The company reported ($0.38) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by ($0.01). research analysts predict that Kura Oncology will post -1.45 EPS for the current fiscal year.
Several hedge funds have recently modified their holdings of the company. California State Teachers Retirement System increased its position in shares of Kura Oncology by 24.5% during the third quarter. California State Teachers Retirement System now owns 31,500 shares of the company’s stock worth $471,000 after acquiring an additional 6,200 shares in the last quarter. Nationwide Fund Advisors increased its position in shares of Kura Oncology by 66.2% during the second quarter. Nationwide Fund Advisors now owns 25,758 shares of the company’s stock worth $240,000 after acquiring an additional 10,258 shares in the last quarter. State of Wisconsin Investment Board bought a new stake in shares of Kura Oncology during the second quarter worth $102,000. Rhumbline Advisers bought a new stake in shares of Kura Oncology during the second quarter worth $131,000. Finally, Schwab Charles Investment Management Inc. increased its position in shares of Kura Oncology by 61.3% during the third quarter. Schwab Charles Investment Management Inc. now owns 39,200 shares of the company’s stock worth $587,000 after acquiring an additional 14,900 shares in the last quarter. 64.26% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This story was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2017/12/04/kura-oncology-kura-downgraded-by-valuengine.html.
About Kura Oncology
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.